Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A critical narrative review analyzing why candidate therapies for cancer therapy-related cognitive impairment fail to translate from preclinical to clinical settings, proposing methodological improvements and a translational roadmap rather than reporting original empirical findings.
Real-world retrospective pharmacy data on persistence and adherence without clinical outcomes, efficacy comparison, or prospective validation; describes treatment patterns rather than clinical benefit or harm.
A single case report of exceptional long-term survival in multiply relapsed SCLC; while clinically striking, the uncontrolled design, inability to attribute benefit to specific interventions, and lack of comparative data mean this raises hypotheses rather than establishing efficacy.
A single case report with a favorable outcome raises a mechanistic question about drug combination efficacy but provides no comparative evidence, control group, or generalizable data to support clinical practice change.
This is an exploratory genomic analysis of publicly available data identifying potential molecular subsets of pancreatic NETs, raising questions about prognostic stratification but lacking validation, clinical outcomes, or therapeutic testing.
A Scientific Statement outlining quality standards and best practices for preclinical cardio-oncology research, intended to promote standardization, reproducibility, and rigor in the field.
A retrospective cohort study with adequate sample size and sound methodology demonstrating that myocardial work parameters detect cardiac dysfunction earlier than ejection fraction, but requiring prospective validation and external replication to confirm clinical utility.
A narrative review synthesizing current evidence on circulating biomarkers in cardio-oncology, recommending multimodal assessment strategies but acknowledging gaps in validation and standardization rather than reporting new primary data.